Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
49
datasets available to search
ShareScore release 0.9.0
Dataset results
49 results for “REM sleep disorder”
Dautan et al 2024 " Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson's Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder"
<p><span>Parkinson’s disease (PD) is characterized by progressive motor as well as less recognized non-motor symptoms that arise often years before motor manifestation, including sleep and gastrointestinal disturbances. Despite the heavy burden on the patient’s quality of life, these non-motor manifestations are poorly understood. To elucidate the temporal dynamics of the disease, we employed a mice model involving injection of alpha-synuclein (αSyn) pre-formed fibrils (PFF) in the duodenum and antrum as a gut-brain model of Parkinsonism. Using anatomical mapping of αSyn PFF propagation and behavioral and physiological characterizations, we unveil a correlation between post-injection time the temporal dynamics of αSyn propagation and non-motor/motor manifestations of the disease. We highlight the concurrent presence of aggregates in key brain regions, expressing acetylcholine or dopamine and their functions in sleep duration, wakefulness, and particularly REM-associated atonia corresponging to REM behavioral disorder-like symptoms. This study presents a novel and in-depth exploration into the multifaceted nature of PD, unraveling the complex connections between α-synucleinopathies, gut-brain connectivity, and the emergence of non-motor phenotypes.</span></p>
Biomarkers of neurodegeneration in isolated and antidepressant-related REM sleep behavior disorder.
<p>Dataset relative to the manuscript "Biomarkers of neurodegeneration in isolated and antidepressant-related REM sleep behavior disorder."</p>
Epigenetic clock estimations in patients with isolated REM Sleep Behavior Disorder
<p>Isolated REM Sleep Behavior Disorder (iRBD) is the strongest prodromal marker for conversion to α-synucleinopathies. A continuum between aging and neurodegeneration has been proposed, but this hypothesis has not been tested in iRBD so far. Here we used epigenetic clocks, estimated from DNA methylation arrays using the DNA Methylation Age Calculator available at https://dnamage.genetics.ucla.edu/home, to measure biological aging in videopolysomnography-confirmed iRBD patients (iRBDs, n=28), videopolysomnography-negative controls (CTR_neg; n=57), and controls from the general population (CTR_pop; n=31)<strong>.</strong></p>
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
ClinicalTrials.gov study NCT02708186. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
ClinicalTrials.gov study NCT04006925. IPD Sharing: NO. Countries: 1. Publications: 4.
Brain Imaging in the Idiopathic REM Sleep Behavior Disorder (ALICE)
ClinicalTrials.gov study NCT03072940. IPD Sharing: Not stated. Countries: 1. Publications: 1.
French Validation of a Severity Scale in REM Sleep Behavior Disorder (SEV-TCSP)
ClinicalTrials.gov study NCT04071899. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease
ClinicalTrials.gov study NCT02789592. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.
Neurobiological Correlates of Post Traumatic Stress Disorder (PTSD) During Rapid Eye Movement (REM) Sleep
ClinicalTrials.gov study NCT00871650. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Establishing Alpha-synuclein RT-QuIC Assay as a Diagnostic Technique in REM Sleep Behaviour Disorder
ClinicalTrials.gov study NCT04266457. IPD Sharing: UNDECIDED. Countries: 1. Publications: 24.
Motor Control During Rapid Eye Movement (REM) Sleep Behaviour Disorder
ClinicalTrials.gov study NCT01886131. IPD Sharing: Not stated. Countries: 1. Publications: 17.
Effect of Clonazepam on REM Sleep Behavior Disorder in Patients With Parkinsonism
ClinicalTrials.gov study NCT02312908. IPD Sharing: UNDECIDED. Countries: 1. Publications: 11.
Data from: Risk factors for possible REM sleep behavior disorder: a CLSA population-based cohort study
Objective: Idiopathic REM sleep behavior disorder (RBD) is a powerful marker of prodromal neurodegenerative synucleinopathy, with 80% of patients ultimately phenoconverting to defined disease. Several environmental risk factors for RBD have been suggested, but associations vary between studies. We assessed sociodemographic, socioeconomic and clinical correlates of RBD in a 30,000-subject national cohort. Methods: Subjects aged 45-85 years in Canada were collected as part of the Canadian Longitudinal Study on Aging. Possible RBD (pRBD) was screened with the RBD-1Q, a questionnaire with 94% specificity and 87% sensitivity. To improve diagnostic reliability, subjects screening positive for apnea or non-REM parasomnia (young onset pRBD), and subjects self-reporting dementia or Parkinson's disease were excluded. A series of sociodemographic, life style and mental health variables were analysed cross-sectionally. Potential correlates were assessed via multivariable logistic regression. Results: Of 30,097 subjects, 958 (3.2%) had pRBD. Male sex (OR=2.14 ,95%CI=[1.84, 2.49]) and lower education (OR=0.95 [0.92, 0.98] were associated with pRBD. pRBD subjects had smoked more (total smoking years OR=1.006 [1.010, 1.011]) and were more likely to be moderate-heavy drinkers (OR=1.25 [1.03, 1.50]). There was a strong association between pRBD and self-reported antidepressant treatment for depression (OR=2.76 [2.22, 3.44]), psychological distress (OR=1.52 [1.37, 1.69]), mental illness (OR=2.08 [1.79, 2.41]), and post-traumatic stress disorder (OR=2.84 [2.55, 3.54]). Conclusions: Our study replicated previous reported associations between pRBD and smoking, low education and male sex, and found previously-unreported links with alcohol use and psychological distress. The risk factors for pRBD differ from those previously defined for neurodegenerative synucleinopathies.
Longitudinal Network Changes and Phenoconversion Risk in Isolated REM Sleep Behavior Disorder
Open the record for dataset details and reuse information.
Longitudinal change in dopamine transporter availability in idiopathic REM sleep behavior disorder
<p><span><b><span>Objective</span></b><span>: </span><span><span>To elucidate longitudinal changes in the dopamine transporter (DAT) availability in association with the prodromal markers in idiopathic rapid-eye-movement sleep behavior disorder (iRBD), we analyzed a longitudinal prospective iRBD cohort data.</span></span></span></p> <p><span><b>Method</b>: The study cohort consisted of iRBD, Parkinson's disease (PD) patients and healthy controls. All participants were evaluated for olfaction, neuropsychological tests, the Movement disorders society-Unified Parkinson's disease Rating Scale and underwent <sup>18</sup>F-FP-CIT PET scans every 2 years. We calculated the DAT pattern by performing the principal component analysis of tracer uptakes in 6 striatal regions.</span></p> <p><span><b>Results</b>: DAT patterns in iRBD patients with baseline hyposmia, constipation and mild parkinsonian signs distributed toward PD-pattern and clearly distinguished from the healthy control pattern. The DAT pattern moved toward PD-pattern over time in some iRBD patients during the follow-up and baseline hyposmia was the only biomarker significantly associated with this change. Baseline PD-pattern of DAT predicted 58% of disease converters (Hazard Ratio=4.95 [1.16~21.08]). The combination of hyposmia and baseline PD pattern of DAT predicted 67% of the conversion (Hazard Ratio=7.89 [1.85~33.69]). The estimated sample size required for a simulated neuroprotective clinical trial was 63 per group when the annual change of DAT pattern was used as an outcome in the subgroup with baseline DAT PD-pattern and hyposmia, which is the smallest number reported so far.</span></p> <p><span><b>Conclusion:</b> Baseline and longitudinal monitoring of the DAT pattern can be a useful biomarker in identifying individuals with a high risk of disease conversion and in selecting the potential population for clinical trials in iRBD.</span></p>
Parkinson's disease-related brain metabolic patterns and neurodegeneration in isolated REM sleep behavior disorder
<p><span><b>Objective</b>: To elucidate the role of Parkinson's disease (PD)-related brain metabolic patterns as a biomarker in isolated rapid-eye-movement sleep behavior disorder (iRBD) for future disease conversion.</span></p> <p><span><b>Method</b>: This is a prospective cohort study consisting of 30 iRBD patients, 25 de novo PD patients with a premorbid history of RBD, 21 long-standing PD patients on stable treatment and 24 healthy controls. iRBD group was longitudinally followed up. All participants underwent <sup>18</sup>F-Fluorodeoxyglucose (FDG) PET and were evaluated with olfaction, cognition, and the Movement disorders society-Unified PD Rating Scale (MDS-UPDRS) at baseline. From FDG-PET scans, we derived metabolic patterns from the long-standing PD group (PD-RP) and de novo PD group with RBD (dnPDRBD-RP). Subsequently, we calculated the PD-RP and dnPDRBD-RP scores in iRBD patients. We validated the metabolic patterns in each PD group and separate iRBD cohort (<i>n</i>=14).</span></p> <p><span><b>Result</b>: The two patterns significantly correlated with each other and were spatially overlapping yet distinct. The MDS-UPDRS motor scores significantly correlated with PD-RP (<i>p</i> = 0.013) but not with dnPDRBD-RP (<i>p</i> = 0.076). In contrast, dnPDRBD-RP correlated with olfaction in butanol threshold test (<i>p</i> = 0.018) in iRBD subjects, but PD-RP did not (<i>p</i> = 0.21). High dnPDRBD-RP in iRBD patients predicted future phenoconversion with all cut-off ranges from 1.5 to 3 standard deviations of the control value, whereas predictability of PD-RP was only significant in a partial range of cut-off.</span></p> <p><b>Conclusion:</b> The dnPDRBD-RP is an efficient neuroimaging biomarker that reflects prodromal features of PD and predicts phenoconversion in iRBD that can be applied individually.</p>
An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)
ClinicalTrials.gov study NCT06996652. IPD Sharing: YES. Countries: 1. Publications: 0.
Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls
ClinicalTrials.gov study NCT03675282. IPD Sharing: NO. Countries: 1. Publications: 0.
DREAMER - IsolateD REM Sleep Without Atonia as a Risk Factor for REM Sleep Behavior disordER
ClinicalTrials.gov study NCT06140511. IPD Sharing: UNDECIDED. Countries: 0. Publications: 19.
Data from: Risk factors for possible REM sleep behavior disorder: a CLSA population-based cohort study
Open the record for dataset details and reuse information.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.